0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Changes in Testing for Human Immunodeficiency Virus, Sexually Transmitted Infections, and Hepatitis C Virus in Opioid Treatment Programs FREE

Marcus A. Bachhuber, MD1; Chinazo O. Cunningham, MD, MS1
[+] Author Affiliations
1Division of General Internal Medicine, Albert Einstein College of Medicine, Bronx, New York
JAMA. 2013;310(24):2671-2672. doi:10.1001/jama.2013.278456.
Text Size: A A A
Published online

Opioid dependence is a risk factor for human immunodeficiency virus (HIV), sexually transmitted infections (STIs), and hepatitis C virus (HCV) infection.1 Opioid treatment programs, which provide treatment to more than 300 000 opioid-dependent individuals in the United States,2 are well-positioned to offer testing for these infectious diseases to a high-risk population. They were among the first venues to offer HIV testing and are more likely to offer HIV, STI, and HCV testing than other drug treatment programs.1 Private for-profit opioid treatment programs are increasingly widespread and such programs offer on-site HIV testing less often than nonprofit and public programs.3 However, with the 2006 national recommendations for routine opt-out HIV testing,4 we hypothesized that the percentage of programs offering on-site testing for HIV, STIs, and HCV would increase.

To determine the percentage of opioid treatment programs offering on-site testing over time, we analyzed the National Survey of Substance Abuse Treatment Services.5 The survey is sent to directors of all known drug treatment facilities (response rate, 91.4%-96.5%); survey questions had minor wording changes over time. We tabulated the percentage of opioid treatment programs offering on-site HIV, STI, and HCV testing from 2000 to 2011; there was no survey in 2001. We compared the percentage of for-profit, nonprofit, and public (owned and operated by local, state, tribal, or federal government) programs offering on-site testing over time. Programs with missing data (0.2%-3.9% per year) were excluded. We calculated the relative difference in programs offering on-site testing in 2000 and 2011 using SAS version 9.3 (SAS Institute Inc). P values were calculated using χ2 tests for trend. A 2-sided P≤.05 was considered significant. Because the survey is publicly available and contains no patient-level data, the Albert Einstein College of Medicine institutional review board determined this study was not considered human research.

The number of US opioid treatment programs increased from 849 in 2000 to 1175 in 2011. The percentage of programs operating as for-profit businesses increased from 43% to 54%, nonprofits decreased from 43% to 36%, and public programs decreased from 14% to 10%. From 2000 to 2011, the absolute number of programs offering testing for HIV, STIs, and HCV increased but the percentage offering on-site testing for HIV declined by 18% (95% CI, 13%-23%; P < .001) and for STIs by 13% (95% CI, 7%-18%; P < .001). There was no significant change for HCV testing (P = .63; Figure 1).

Place holder to copy figure label and caption
Figure 1.
US Opioid Treatment Programs Offering Testing for Human Immunodeficiency Virus (HIV), Sexually Transmitted Infections (STIs), and Hepatitis C Virus (HCV) From 2000 to 2011

aRefers to revised recommendations from the US Centers for Disease Control and Prevention in 2006 to screen all adults, adolescents, and pregnant women for HIV infection in all health care settings, unless the patient declines.4bOn-site testing specifically for HCV was recorded starting in 2003.

Graphic Jump Location

More than 75% of public programs offered on-site testing for each infection, with no significant change over time. Offering on-site HIV testing declined by 20% (95% CI, 10%-29%; P < .001) among for-profit programs and by 11% (95% CI, 6%-17%; P < .001) among nonprofit programs (Figure 2). Offering on-site STI testing declined by 23% (95% CI, 16%-30%; P < .001) in for-profit programs. Offering HCV testing declined by 13% (95% CI, 3%-22%; P = .002) in for-profit programs and increased by 14% (95% CI, 4%-25%; P < .001) in nonprofit programs.

Place holder to copy figure label and caption
Figure 2.
For-Profit, Nonprofit, and Publicly Owned US Opioid Treatment Programs Offering On-Site Human Immunodeficiency Virus (HIV) Testing From 2000 to 2011

aRefers to revised recommendations from the US Centers for Disease Control and Prevention in 2006 to screen all adults, adolescents, and pregnant women for HIV infection in all health care settings, unless the patient declines.4

Graphic Jump Location

The proportion of US opioid treatment programs offering on-site testing for HIV and STIs declined substantially between 2000 and 2011, despite guidelines recommending routine opt-out HIV testing in all health care settings, including substance abuse treatment facilities. Declines were most pronounced in for-profit programs, suggesting that persons enrolled in these programs may be at increased risk for delayed diagnosis and continued transmission of HIV, STIs, and HCV.

This study had limitations. Referral-based testing was not recorded; however, referral-based services often do not translate into patient use.6 Testing for STIs may be limited to syphilis, which is often required by health departments. The survey is cross-sectional with no identifiers linking responses over time. Because patient-level data are not available, patient requests, use, and opting out of testing cannot be determined.

Opioid treatment programs are important venues for offering testing to high-risk individuals. As the number of for-profit opioid treatment programs increases, and the opioid, HIV, and HCV epidemics continue to intersect, further work is needed to understand and reverse declines in offering on-site testing.

Section Editor: Jody W. Zylke, MD, Senior Editor.

Corresponding Author: Chinazo O. Cunningham, MD, MS, Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467 (ccunning@montefiore.org).

Author Contributions: Dr Bachhuber had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Bachhuber.

Acquisition of data: Bachhuber.

Analysis and interpretation of data: Bachhuber, Cunningham.

Drafting of the manuscript: Bachhuber, Cunningham.

Critical revision of the manuscript for important intellectual content: Bachhuber, Cunningham.

Statistical analysis: Bachhuber.

Obtained funding: Cunningham.

Study supervision: Cunningham.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Cunningham’s husband was recently employed by Pfizer Pharmaceuticals and is currently employed by Quest Diagnostics. No other disclosures were reported.

Funding/Support: This study was supported by grants R34DA031066, R01DA032110, R25DA023021, and AI-51519 from the National Institutes of Health.

Role of the Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Office of Applied Studies, Substance Abuse and Mental Health Services Administration. The N-SSATS Report: infectious disease screening. http://www.oas.samhsa.gov/2k10/227/227DiseaseScreen2k10.htm. Accessibility verified November 15, 2013.
Substance Abuse and Mental Health Services Administration. The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
Pollack  HA, D’Aunno  T.  HIV testing and counseling in the nation’s outpatient substance abuse treatment system, 1995-2005. J Subst Abuse Treat. 2010;38(4):307-316.
PubMed   |  Link to Article
Branson  BM, Handsfield  HH, Lampe  MA,  et al; Centers for Disease Control and Prevention (CDC).  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
PubMed
Office of Applied Studies, Substance Abuse and Mental Health Services Administration. The DASIS report: the National Survey of Substance Abuse Treatment Services (N-SSATS). http://www.samhsa.gov/data/2k3/NSSATS/NSSATS.pdf. Accessibility verified November 15, 2013.
Metsch  LR, Feaster  DJ, Gooden  L,  et al.  Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160-1167.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.
US Opioid Treatment Programs Offering Testing for Human Immunodeficiency Virus (HIV), Sexually Transmitted Infections (STIs), and Hepatitis C Virus (HCV) From 2000 to 2011

aRefers to revised recommendations from the US Centers for Disease Control and Prevention in 2006 to screen all adults, adolescents, and pregnant women for HIV infection in all health care settings, unless the patient declines.4bOn-site testing specifically for HCV was recorded starting in 2003.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
For-Profit, Nonprofit, and Publicly Owned US Opioid Treatment Programs Offering On-Site Human Immunodeficiency Virus (HIV) Testing From 2000 to 2011

aRefers to revised recommendations from the US Centers for Disease Control and Prevention in 2006 to screen all adults, adolescents, and pregnant women for HIV infection in all health care settings, unless the patient declines.4

Graphic Jump Location

Tables

References

Office of Applied Studies, Substance Abuse and Mental Health Services Administration. The N-SSATS Report: infectious disease screening. http://www.oas.samhsa.gov/2k10/227/227DiseaseScreen2k10.htm. Accessibility verified November 15, 2013.
Substance Abuse and Mental Health Services Administration. The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
Pollack  HA, D’Aunno  T.  HIV testing and counseling in the nation’s outpatient substance abuse treatment system, 1995-2005. J Subst Abuse Treat. 2010;38(4):307-316.
PubMed   |  Link to Article
Branson  BM, Handsfield  HH, Lampe  MA,  et al; Centers for Disease Control and Prevention (CDC).  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
PubMed
Office of Applied Studies, Substance Abuse and Mental Health Services Administration. The DASIS report: the National Survey of Substance Abuse Treatment Services (N-SSATS). http://www.samhsa.gov/data/2k3/NSSATS/NSSATS.pdf. Accessibility verified November 15, 2013.
Metsch  LR, Feaster  DJ, Gooden  L,  et al.  Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160-1167.
PubMed   |  Link to Article

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com